PCH
CRNX icon

Polar Capital Holdings’s Crinetics Pharmaceuticals CRNX Stock Holding History

Polar Capital Holdings’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.1M Buy
+2,274,411
New +$84.5M 0.2% 94

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Polar Capital Holdings's CRNX Position: Q2 2026 in Review

Polar Capital Holdings opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 2,274,411 shares worth $85.1M. The stake represents 0.2% of the portfolio and ranks #94 among its holdings.

231 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Polar Capital Holdings held 2,274,411 shares of Crinetics Pharmaceuticals worth $85.1M as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Polar Capital Holdings position in Q2 2026.
  • Crinetics Pharmaceuticals made up 0.2% of Polar Capital Holdings's portfolio in Q2 2026, its #94 holding.
  • 231 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.